|
|
 |
Overseeing the editorial content and development of the journal is an Editorial Board, composed of many of the world's leading experts within the area of drug discovery and development.
- Sudhir Agrawal - Hybridon, USA
- Gary P Anderson - University of Melbourne, Australia
- Koshi Arai - Taisho, Japan
- John F Barrett - Merck & Co Inc, USA
- Robert Beamer - University of South Carolina, USA
- Nigel Beeley - Arena Pharmaceuticals, USA
- Stanley C Bell - Allelix Neuroscience, Canada
- Francois D Bellamy - Laboratoires Fournier, France
- Scott Biller - Novartis Institute for Biomedical Research, USA
- Frederik Bjorkling - Leo Pharmaceuticals, Denmark
- David P Bloxham - Evolutec, UK
- Mike Briley - NeuroBiz, France
- James A Bristol - Pfizer Inc, USA
- Clint Brooks - Abbott Laboratories, USA
- Leslie J Browne - Iconix Pharmaceuticals Inc, USA
- Andre Bryskier - Aventis, France
- Simon Campbell - Ex-Pfizer, UK
- Roberto Ceserani - Roche, Italy
- Daniel TW Chu - Chiron Corp, USA
- John C Clapham - Astra Zeneca, UK
- Tom Colatsky - Paradigm Genetics, USA
- Stanley T Crooke - ISIS Pharmaceuticals, USA
- Roger Crossley - BioFocus, UK
- Erik de Clercq - Rega Institute for Medical Research, Belgium
- Robert E Davis - ACADIA Pharmaceuticals, USA
- Scott Dax - RW Johnson Pharmaceutical Research Institute, USA
- Annette Doherty - Pfizer, France
- J. Drews - Ex-Hofmann-La Roche, USA
- Gerard Emilien - Catholic University of Louvain, France
- Jay Gibbs - Merck Research Laboratories, USA
- Steven Gillis - Corixa Corporation, USA
- William E Heydorn - Forest Laboratories, USA
- Ray Hill - Merck & Co, UK
- Richard Houghten - Torrey Pines Institute for Molecular Studies, USA
- Victor J Hruby - University of Arizona, USA
- Ian Hunneyball - EVOTEC, UK
- Kim D Janda - The Scripps Research Institute, USA
- Graham Johnson - Rib-X Pharmaceuticals, USA
- Taff (David H) Jones - ID Biomedical Corp, Canada
- Ulrich Jordis - Institute of Applied Synthetic Chemistry, Austria
- Barry L Karger - Northeastern University, USA
- Mads Krogsgaard Thomsen - Novo Nordisk, Denmark
- Donald J Kyle - Purdue Pharma, USA
- Kit S Lam - US Davis Cancer Center, USA
- Gerard Le Fur - Sanofi Synthelabo, France
- Alex Levitzki - Hebrew University, Israel
- Ronald Magolda - Boehringer Ingelheim, USA
- John P Mallamo - Cephalon, USA
- Paolo Mascagni - Italfarmaco, Italy
- John M McCall - Pharmacia, USA
- Lester A Mitscher - University of Kansas, USA
- Brett P Monia - ISIS Pharmaceuticals, USA
- Walter H Moos - MitoKor, USA
- F Richard Nichol - CoCensys, USA
- Kyriacos C Nicolaou - The Scripps Research Institute, USA
- Peter E Nielsen - The Panum Institute, Denmark
- A Nistri - International School for Advanced Studies, Italy
- Stella O'Donnell - University of Queensland, Australia
- Jill Ann Panetta - Lilly Research Laboratories, USA
- Norton P Peet - Aurigene Discovery Technologies, USA
- George Perry - University of Texas at San Antonio, USA
- Petpiboon Peppi Prasit - Merck Research Laboratories, Canada
- Edward Petrillo - Bristol-Myers Squibb, USA
- George Poste - Health Technology Networks, USA
- PRK Reddy - University of Hyderabad, India
- Daniel H Rich - University of Wisconsin-Madison, USA
- Erich Schlick - Knoll, Germany
- Naj Sharif - Alcon Laboratories, USA
- Robert D Sindelar - University of British Columbia, Canada
- Keith Suckling - GlaxoSmithKline, UK
- Mark J Suto - Neurion Pharmaceuticals, USA
- Grace Tang - The University of Hong Kong, Hong Kong
- Bernard Testa - Lausanne University, Switzerland
- David J Triggle - State University of New York at Buffalo, USA
- Marc Vasseur - GENSET, France
- Michael D Varney - Pfizer, USA
- Ruth R Wexler - Bristol-Myers Squibb, USA
- George Whitesides - Harvard University, USA
- Wendell Wierenga - Syrrx Inc, USA
- Michael Williams - Northwestern University, USA
- Zbigniew Witczak - Wilkes University, USA
- Paul L Wood - OxoN Medica, USA
|
|
|
|
